BB Biotech Benefits from Improved Market Environment
BB Biotech reported a 2025 net profit of 578 million francs, up from 76 million in 2024, citing stabilised markets and active portfolio management; it added stakes in Amicus Therapeutics, Nuvalent, Krystal Biotech, Jade Biosciences, Maze Therapeutics and Tango Therapeutics, increased positions in Scholar Rock and Viridian, completed divestments including Macrogenics, saw five portfolio companies acquired, raised the dividend to CHF 2.25, and announced board changes with Mads Krogsgaard Thomsen nominated as vice chairman.
Why it mattersBB Biotech's 578 million-franc profit and stakes in Amicus Therapeutics signal reallocating portfolio weight toward rare-disease assets.